bapes

Bulgarian Association for Promotion of Education And Science (BAPES), Bulgaria

Established in 2003, the Bulgarian Association for Promotion of Education and Science (BAPES), NONGOVERNMENTAL NON-PROFIT ORGANISATION, is working to increase the knowledge on rare diseases among the medical community and the society as whole in Bulgaria. By participating in a number of major EU-funded projects, implementing a series of epidemiological registries and organising targeted educational and scientific events, BAPES helps to stimulate fundamental, clinical and public health research on rare diseases in Bulgaria, as well to develop and provide care and services for people with rare diseases and their families. BAPES consecutively launched the Information Centre for Rare Diseases and Orphan Drugs, ICRDOD (2004) and the “RareDis” Medical Centre (2009). A volunteer team, comprised of 23 leading medical professionals, stands behind the efforts of ICRDOD, which has created an extensive rare disease open access online education library in Bulgarian language. BAPES launched a third new project activity in 2013 – the Centre for Health Technology Assessment and Analysis, CAHTA, introducing and building capacity in Bulgaria for conducting rare disease-specialised health technology assessment. Starting from September 2013, the three main project activities of BAPES – ICRDOD, “RareDis” and CAHTA – have been territorially and functionally united into a single institution – the Institute for Rare Diseases, the very first and only interdisciplinary and multifunctioning rare disease institution in Eastern Europe.

LEADER

Rumen, Stefanov, MD, PhD.
Rumen, Stefanov, MD, PhD.Chair of BAPES, Director of the Institute for Rare Diseases
Years of experience: 18
Specific expertise: Rare Diseases Epidemiology Research; Rare Diseases Registry; Rare Disease Policy Making; Demography; Biostatistics.

Rumen, Stefanov, MD, PhD.

  • MD (Medical Doctor), Medical University of Plovdiv, 1997
  • Specialist in Public Health, Medical University of Plovdiv, 2003
  • PhD in Public Health, Medical University of Plovdiv / High Attestation Commission, 2004
  • Assistant Professor of Public Health, Medical University of Plovdiv, 1998 – 2006
  • Visiting researcher, Mario Negri Institute for Pharmacological Research, 2001 – 2004
  • Chair of BAPES, 2003 –
  • Member, European Commission Task Force on Rare Diseases, 2004 – 2009
  • Associate Professor of Public Health, Medical University of Plovdiv, 2006 – 2012
  • Dean of the Faculty of Public Health at the Medical University of Plovdiv, 2010 –
  • Member, Interdisciplinary Committee of the International Rare Diseases Research Consortium, 2012 –
  • Member, EU Committee of Experts on Rare Diseases, 2013
  • Member, Commission Expert Group on Rare Diseases, 2013 –
  • Full Professor of Public Health, Medical University of Plovdiv, 2012 –
  • Director of the Institute for Rare Diseases, 2013 –
  • Member, Board of Member States on European Reference Networks, 2014 –
  • Public health Research.
  • Epidemiology Research in Rare Diseases.
  • Health information systems including Registries, prevalence studies and early screening studies.
  • Health policy
  • Health care system
  • Demography
  • Biostatistics

TEAM

Georgi Iskrov, MBA.

  • BSci in Computer Science, University of Plovdiv, 2010
  • Master in Business Administration, University of Plovdiv, 2012
  • PhD in Public Health, Medical University of Plovdiv, 2013 – 2016.
  • Master in Public Health, Medical University of Plovdiv, 2014 – 2016
  • Director, Centre for Health Technology Assessment and Analyses, BAPES, 2013 –
  • European Projects Manager, Information Centre for Rare Diseases and Orphan Drugs, 2008 – 2013
  • Researcher in various EU-funded projects (EUROPLAN, BURQOL-RD, RARE Best Practices), 2008 – present
  • Public health Research
  • Health policy
  • Health economics
  • Health technology assessment
  • Project management
Georgi Iskrov, MBA
Georgi Iskrov, MBADirector, Centre for Health Technology Assessment and Analyses, BAPES
Years of experience: 6
Specific expertise: Public Health, Rare Diseases, Orphan Drugs, Health Technology Assessment, Drug Policy, Policy Making